Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D. Patnaik A, et al. Among authors: tsai f. Cancer Chemother Pharmacol. 2018 Sep;82(3):407-418. doi: 10.1007/s00280-018-3623-7. Epub 2018 Jun 20. Cancer Chemother Pharmacol. 2018. PMID: 29926131 Free PMC article. Clinical Trial.
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. Luke JJ, et al. Among authors: tsai f. J Immunother Cancer. 2021 Feb;9(2):e002015. doi: 10.1136/jitc-2020-002015. J Immunother Cancer. 2021. PMID: 33608377 Free PMC article. Clinical Trial.
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D. Patnaik A, et al. Among authors: tsai f. Cancer Chemother Pharmacol. 2018 Sep;82(3):419. doi: 10.1007/s00280-018-3641-5. Cancer Chemother Pharmacol. 2018. PMID: 30014222 Free PMC article.
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting.
Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O'Donoghue JA, Ziolkowska M, Ruan S, Lyashchenko SK, Tsai F, Farwell M, Mitchell TC, Korn R, Le W, Lewis JS, Weber WA, Behera D, Wilson I, Gordon M, Wu AM, Wolchok JD. Pandit-Taskar N, et al. Among authors: tsai f. J Nucl Med. 2020 Apr;61(4):512-519. doi: 10.2967/jnumed.119.229781. Epub 2019 Oct 4. J Nucl Med. 2020. PMID: 31586002 Free PMC article. Clinical Trial.
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Among authors: tsai f. Invest New Drugs. 2024 Feb;42(1):145-159. doi: 10.1007/s10637-023-01410-2. Epub 2024 Feb 7. Invest New Drugs. 2024. PMID: 38324085 Free PMC article. Clinical Trial.
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.
Rodon J, Rodriguez E, Maitland ML, Tsai FY, Socinski MA, Berlin JD, Thomas JS, Al Baghdadi T, Wang IM, Guo C, Golmakani M, Clark LN, Gazdoiu M, Li M, Tolcher AW. Rodon J, et al. Among authors: tsai fy. ESMO Open. 2024 Apr;9(4):102961. doi: 10.1016/j.esmoop.2024.102961. Epub 2024 Apr 18. ESMO Open. 2024. PMID: 38640748 Free PMC article. Clinical Trial.
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Among authors: tsai f. Invest New Drugs. 2024 Jun;42(3):340-341. doi: 10.1007/s10637-024-01444-0. Invest New Drugs. 2024. PMID: 38767685 Free PMC article. No abstract available.
2,190 results